This is good. Combination of Ceftazidime+Avibactum is one of the very few therapeutic options available to treat multidrug resistant(MDR) gram negative bacterial infection (particularly Enterobacteriaceae family) which are increasing significantly in India. These are resistant to carbapenem drugs(eg:Meropenem, Gufic does have good product portfolio of carbapenems) , Ceftazidime+Avibactum has emerged as one of the main treatment options in critical care in such cases. As I have seen , use of this particular antibiotic has increased exponentially in last 2 years in higher medical center’s and likely that the use will increase further as overall incidence of MDR bugs are increasing and more awareness of product among practitioners. Increase in availability of detecting particular enzyme causing drug resistance also contributing to selecting Ceftazidime+Avibactum as treatment option.
Presently only Zevicefta by Pfizer ltd is available in market. The standard dose( Ceftazidime 2gm/Avibactum 0.5gm) vial is marketed at around MRP Rs.4500.00
Today Gufic concall is scheduled at 4.30PM, we may get more details about product pricing, growth and market size.
(One of their main product in critical care, Meropenem has come under NLEM list. We can ask management about impact of same on critical care segment revenue. My guess is it will be at least 15-20% of their critical care revenue).
Discl: tracking.
| Subscribe To Our Free Newsletter |
